IPN - Instituto Pedro Nunes - Instituto Pedro Nunes plays a key role in the EIT Health Network in Portugal in 2024

IPN     IPN Incubadora
Instituto Pedro Nunes plays a key role in the EIT Health Network in Portugal in 2024
General
 
Clique aqui para a versão em português.


The EIT Health Network aims to build an ecosystem that enables the development of healthcare for the future, so that European citizens can live longer and healthier lives. In 2024, Instituto Pedro Nunes (IPN) is playing a key role in various EIT Health programmes, including bootcamps in the area of entrepreneurial and technological innovation in the health sector.

MedTech Bootcamp
The MedTech Bootcamp is a six-week online programme aimed at early-stage medtech and digital health start-ups, led by FAU Erlangen-Nürnberg, one of Germany's largest research universities, in partnership with IPN and IESE. IPN is responsible for organising the "Business Design" module. The deadline for applications is 21 May. More information here.

Women Entrepreneurship Bootcamp
The Women Entrepreneurship Bootcamp aims to boost female entrepreneurship in the healthcare sector and is led by IESE, in collaboration with IPN and the University of Galway. IPN is responsible for the "Leadership, Regulation, and Communication" module. The deadline for registration is 25 March. More details here.

PATH - Regulatory Pathways to Market Bootcamp
IPN is coordinating the PATH - Regulatory Pathways to Market Bootcamp, which has the support of partners Medical Valley, Medtronic Portugal, Medtronic Iberia, Syreon Research Institute and Complear. This bootcamp, focussed on helping early-stage healthcare companies enter the European market, reinforces IPN's commitment to the regulation of medical devices. More information can be found here.

Since 2022, IPN has hosted the EIT Health InnoStars headquarters in Portugal, consolidating its position as a centre for innovation in the country's healthcare sector. Ongoing collaboration with the University of Coimbra also plays a crucial role in the ongoing development of innovative medical solutions.

Data

29 de Janeiro de 2024

Partilhar